Sign In  |  Register  |  About Walnut Creek Guide  |  Contact Us

Walnut Creek, CA
September 01, 2020 1:43pm
7-Day Forecast | Traffic

  • Search Hotels in Walnut Creek Guide

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Moderna Inc (NQ: MRNA )

41.11 +2.86 (+7.48%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Moderna Inc

< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
99 100 Next >
BioNTech Shifted Its Focus To Innovative Oncology And Mainz Biomed Announced A Showcasing Of Its Revolutionary Colorectal Cancer Detection Test
On November 6th, BioNTech SE (NASADQ: SE) who partnered with Pfizer Inc (NYSE: PFE) in the making of a blockbuster COVID-19 vaccine, posted a surprise earnings with its latest quarterly report. 
Via Benzinga
Exposures COVID-19
Moderna Tops BioSpace’s Best Places to Work Ranking for Third Consecutive Year
Via ACCESSWIRE
Is It Time to Buy the S&P 500's 4 Worst-Performing Stocks This Year?
Should you buy the dip on these S&P 500 stocks? 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Cathie Wood Just Bought This Struggling Stock After Its Billion-Dollar Quarterly Loss. Should You?
This particular stock has dropped more than 50% this year. 
Via The Motley Fool
Like Moderna, BioNTech Cuts Annual Sales Forecast By 20% As Pandemic Fades
BioNTech SE (NASDAQ: BNTX) has reported Q3 revenues of €895.3 million ($974.49 million), sharply down from €3.461 billion a year ago. 
Via Benzinga
Why Moderna Stock Plummeted by Almost 7% Today
Many investors felt queasy after reviewing the company's latest earnings report. 
Via The Motley Fool
Moderna Reports Third Quarter 2023 Financial Results and Provides Business Updates
Via ACCESSWIRE
Check Out What Whales Are Doing With MRNA
Via Benzinga
Down 84% From Its Peak. Is It Finally Time to Buy Moderna?
The vaccine developer's huge profits have turned into heavy losses. 
Via The Motley Fool
Moderna May Be Facing Its Toughest Moment Ever. Time to Sell?
Moderna still has big ambitions -- beyond the coronavirus vaccine -- that could pay off in a few years. 
Via The Motley Fool
Exposures COVID-19
These Analysts Cut Their Forecasts On Moderna After Q3 Results
Moderna Inc (NASDAQ: MRNA) posted a loss for the third quarter on Thursday. 
Via Benzinga
Cyberark Software To Rally Around 21%? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Cathie Wood's Ark Invest Goes Shopping For Moderna Stock — Sells DraftKings Shares Amid Quarterly Rise In Revenue, EPS Beat
Via Benzinga
Apple, AMD, Palantir Earnings On Deck This Week As Market Seeks Positive Catalysts In Fed Decision Week
S&P 500 earnings is expected to grow in Q3, reversing a four-quarter slide, as the reporting season enters its third week. 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Earnings Recap: Shell, Palantir, Starbucks, Shopify Rise; Moderna Falls
Shares of Shell, Palantir, Starbucks, and Shopify all rose higher on Thursday following better-than-expected earnings reports. 
Via Talk Markets
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Moderna (MRNA) Q3 2023 Earnings Call Transcript
MRNA earnings call for the period ending September 30, 2023. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Moderna Struggles With Weaker COVID-19 Vaccine Demand, Expects To Return To Growth In 2025, Stock Plunges
Moderna Inc (NASDAQ: MRNA) shares are trading lower after the company reported a deeper Q3 loss of $(9.53), down from EPS income of $2.53. 
Via Benzinga
Exposures COVID-19
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
US Stocks On Track For Solid Start Amid Lingering Fed Optimism: Traders Eye Earnings From Market Bellwether Apple
After the Federal Reserve‘s decision, the stock market rally is poised to gain momentum on Thursday, with stock futures indicating an uptick. 
Via Benzinga
Topics Economy
Exposures Interest Rates
Moderna Beats Sales Forecasts, But Light Guidance Could Rattle Shares
The company issued below-consensus sales views for 2023 and 2024. 
Via Investor's Business Daily
Healthcare Playbook: Hardly Defensive With A Covid Hangover In Biotech
Market Bubbles may take a long time to clear and we created a big one in July 2021 dealing with the COVID pandemic. 
Via Talk Markets
Exposures COVID-19
McCormick, CME Group And 2 Other Stocks Insiders Are Selling
The Nasdaq 100 closed higher by 0.5% on Friday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
CEPI and Moderna Harness mRNA Technology to Advance 100 Days Mission
Via ACCESSWIRE
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Got $2,000? Here Are 2 Beaten-Down Growth Stocks to Buy Right Now
Now, you can scoop up these future growth winners for a bargain. 
Via The Motley Fool
Moderna Named a Top Employer by Science for Ninth Consecutive Year
Via ACCESSWIRE
Why Pharma Giant Merck's Shares Are Shooting Higher Today
Merck & Company, Inc. (NYSE: MRK) Q3 sales reached $15.962 billion, up 7% Y/Y, beating the consensus of $15.320 billion,  
Via Benzinga
Vertex Pharmaceuticals: Buy at the High?
Vertex shares have been flying high in recent times. 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 WalnutCreekGuide.com & California Media Partners, LLC. All rights reserved.